TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Metrological Properties of Two Assessment Grids of the Driving Capacity After a Cerebrovascular Accident (ROADTRIP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 Years to 80 Years~* Cognitive and/or sensitive-motor disorders after a cerebrovascular accident~* Candidate for resumption of driving on the road and having to pass an aptitude test~* French legal protection~Exclusion Criteria:~* Contraindications for resumption of driving on the road (visual field amputation, binocular visual acuity less than 5/10; cognitive impairment not compatible with driving; other medical contraindication).~* Protected populations not concerned by the study (guardianship, curatorship, deprived of the freedoms, safeguarding of justice).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Behavoiral (Type: EXPERIMENTAL): The evaluation will be realized on two different assessment grids during the test on the road

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The CHOICE Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18~2. Diagnosis of metastatic CRC~3. Having completed first and second lines of treatment for metastatic CRC~4. Intending (at time of enrollment) to initiate a third (or subsequent) line of treatment~5. Ability to understand and read English or Spanish~6. Willing and able to sign an Informed Consent Form (ICF), or have a Legally Authorized Representative willing and able to consent on the patient's behalf~Exclusion Criteria:~1. Patient is unwilling or unable to participate in the Registry at the time of enrollment~2. The patient is currently participating in an investigational clinical trial~3. Patients not having mental capacity and or ability to participate in the Registry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exercise & Tart Cherry Ingestion on Heat Acclimation and Gut Microbiome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* 18-55 years old~* Recreational cyclists (\>150 minutes per week of cycling exercise)~* VO2max \>60th percentile according to ACSM~Exclusion Criteria:~* Previous episode of heat illness, such as heat syncope, heat exhaustion or heat stroke~* Known cardiopulmonary disease, metabolic disorders, Parkinsons Disease, or multiple sclerosis or other autonomic nervous system conditions~* diagnosed with or being treated for arthritis or any inflammatory condition (such as Lupus, gout, or Sjogrens syndrome)~* Known or suspected orthostatic hypotension or low blood pressure~* Known issues with cooling or sweating~* currently smoke or quit smoking less than one year ago~* not willing to self-insert a flexible, thin (3 mm) vinyl rectal probe and maintain this position throughout all exercise sessions.~* not willing to have blood drawn pre-supplementation and 4 times during heat stress test trials (a total of 10 times during the study).~* not willing to provide a stool sample pre- and post-heat stress tests (4 total samples).~* allergy to cherries or food dyes

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Experimental: tart cherry (Type: EXPERIMENTAL): dietary supplement: tart cherry juice
- Placebo (Type: PLACEBO_COMPARATOR): dietary supplement: placebo juice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exercise in Patients With a Total Coronary Occlusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Single vessel disease with a chronic total occlusion of the right coronary artery, left anterior descending artery, or left circumflex artery, as identified on coronary angiography performed within the preceding 24 months.~* Willingness to undertake maximal cardiopulmonary exercise test~* Resting systolic blood pressure \<180mmHg~* Resting Diastolic blood pressure \<100mmHg~* Aged \>18yrs~* Normal resting left ventricular function~* Able to provide written informed consent~Exclusion Criteria:~* Significant proximal left main stem stenosis.~* Multi-vessel disease (defined as a diameter stenosis of \>50% in another major epicardial coronary vessel)~* Absence of exercise-induced ischaemia evidenced by O2/HR or, ΔVO2/ ΔWR inflection at visit 1 and 2~* O2/HR inflection or, ΔVO2/ ΔWR inflection at a respiratory exchange ratio \>1.05~* Change in cardiac medications within previous two weeks~* Unstable angina~* Myocardial infarction within the preceding 6 weeks~* Canadian classification system for angina class IV~* Chronic heart failure~* Significant valvular pathology~* Resting ejection fraction \<40%~* Severe orthopaedic limitations~* Past history of Complex arrhythmias~* Atrial fibrillation~* Severe COPD~* Symptoms of intermittent claudication~* Unable to provide written informed consent~* Previous permanent pacemaker implant~* Use of short-term GTN within 30 minutes of exercise testing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CTO Exerciser (Type: EXPERIMENTAL): 2x Symptom limited cardiopulmonary exercise tests~1x Sub-maximal cardiopulmonary exercise test (20 minutes)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Implementing Cabenuva in Arkansas HIV Programs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons, 18-years old and older~* Receiving Cabenuva injections (following registered USPI) at one of the six clinics in this study~* Ability to provide informed consent~* Patients who would receive Cabenuva at home: Living within 40-miles from the three clinics randomized to the at-home arm of the study~Exclusion Criteria:~* Pregnant or breastfeeding women, or women who plan to become pregnant during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clinic visit arm (Type: NO_INTERVENTION): Patient will receive Cabenuva injection at the clinic
- Home visit arm (Type: EXPERIMENTAL): Patient will receive Cabenuva injection at home

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Novel E-health Platform

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 25-70 years old~Exclusion Criteria:~* don't speak or read English~* no home internet access~* a baseline PWB score of 4.5 or greater

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Control Group: (PWG 1.0) (Type: ACTIVE_COMPARATOR): Those randomized to PWG 1.0 would have already completed their serious illness medical planning. Further involvement in the trial will be solely for the purposes of the outcome data collection
- Intervention group: PWG 2.0 (Type: ACTIVE_COMPARATOR): Serious illness medical planning plus the novel e-health platform designed to help people more broadly think and plan ahead

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* More than 18 years old.~* Epidermoïde carcinoma or adenocarcinoma of the cervix, hystologic proved~* Patientes in a late stage or with progresive desease.~* One mesurable lesion in irradiated zone.~* Patient who have already treated radio-chimiothérapy with platine should have a 6 month free interval.~* Index status of ECOG ( Eastern Cooperative Oncology Group )less than 2.~* Good biologicals and hematologicals fonctions:~* Neutrophiles noless than 1,5.109/L.~* Platelets nolss than 100.109/L.~* Total bilirubin no more than 1,5 time the normal superior range.~* Transaminases no mote than 3 x Time NSR~* Creatinine clairance Cockroft) more than 50 mL/min .~* Inform consent signed.~Exclusion Criteria:~* Previous cytotoxic traitement exept radio-chaemiotherapy of the pelvis cerebrals metastasis.~* Other cancer in the last 5 years exept treated BCC.~* Dermatologic desease.~* Crohn desease or Hemorragic rectal-Colitis.~* Neuropathy.~* Psychologic disorder.~* Social troubles.~* Pregnant women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* single enhancing lesion of the brain with MRI appearance consistent with GBM~* Must be appropriate for Gliadel® wafer implant~* Pathologic confirmation of GBM~* no gross residual tumor found on the immediate postoperative MRI scan~* Volumetric measurements of the resection cavity margin being \< 50 cc~* Karnofsky performance status (KPS) 80% or better~* Must be able to undergo MRI imaging with gadolinium~* Willingness to have follow up visits at Barrow Neurological Institute(BNI)~Exclusion Criteria:~* multi-focal tumors~* tumors which extend across the corpus callosum,~* residual nodular disease~* Tumors, with a contraindication to Gliadel® implant, such as an anticipated extensive ventricular opening resulting from complete resection.~* Tumor measuring greater than 50cc in volume (on post-operative scan) Volume \< 50 cc if volume if a significant volume of eloquent tissue is included in the proposed treatment volume~* Unable to undergo MRI with gadolinium~* History of cancer within 2 years of GBM diagnosis (basal and squamous cell skin cancers are allowed)~* Patient is not willing to follow up at BNI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GammaKnife(R) stereotactic radiosurgery (Type: EXPERIMENTAL): Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive a one-day GammaKnife(R) stereotactic radiosurgery procedure and will also take temozolomide (Temodar(R)) chemotherapy daily for six weeks with a one month break before taking temodar for additional 12 monthly cycles.
- Standard fractionated radiation therapy (Type: ACTIVE_COMPARATOR): Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive six weeks of standard fractionated radiation therapy plus daily temozolomide (Temodar(R)) chemotherapy for six weeks. This is followed by a one month break before taking temodar for additional 12 monthly cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Stereotaxis Idiopathic Ventricular Tachycardia (VT) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be between 18 - 80 years of age~* Willing to provide written informed consent~* Present with ventricular ectopy of non-ischemic origin~* able to be safely exposed to a static magnetic field~* Failure of at least 1 antiarrhythmic medication~Exclusion Criteria:~* Presence of a mobile ventricular thrombus~* Unable to obtain percutaneous access to the left ventricle~* Contraindicated for short-term anticoagulation therapy~* Life expectancy less than 1 year~* Body habitus limits placement on the procedure table~* Previously failed ablation procedure for VT/PVCs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: None): Ablation of VT/PVCs using a magnetic RF ablation catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pathologically confirmed of head and neck cancer~* plan to have chemoradiotherapy session~* Performance status of 0-2~Exclusion Criteria:~* contraindications for percutaneous gastrostomy, eg coagulopathy, obstructed tumor~* Body mass index less than 16 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control (Type: NO_INTERVENTION): nutrition counselling with nasogastric tube insertion in the cases of weight loss more than 10% or severe mucositis developed during chemoradiotherapy
- prophylactic percutaneous gastrostomy (Type: EXPERIMENTAL): prophylactic percutaneous gastrostomy with nutrition counselling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of T-Cell lymphoma with mandatory pathologic review at Brigham and Women's Hospital or Massachusetts General Hospital~* Measurable disease~* Candidate for Autologous Stem Cell Transplant~Exclusion Criteria:~* Prior anti-lymphoma chemotherapy (except steroids/radiotherapy for urgent palliation, one prior cycle of CHOP or up to 2 prior cycles of CHOEP)~* Pregnant or breastfeeding~* Alk-positive ACL~* Significant neuropathy precluding vincristine administration~* Known hypersensitivity to any of the agents used in the treatment~* Uncontrolled intercurrent illness~* Receiving other investigational agents~* History of a different malignancy except if disease free for at least 5 years or have cervical cancer in situ or basal cell/squamous cell carcinoma of the skin~* HIV positive on anti-retroviral therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CHOEP + High Dose Therapy + Auto SCT (Type: EXPERIMENTAL): Patients received 6 cycles of induction chemotherapy: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide and Prednisone (CHOEP) (5 if previously received 1 cycle of CHOP). CHOP was given at standard doses, with a dose of etoposide of 100 mg/m2 intravenously (IV) or 200 mg/m2 orally added on days 1-3 of each cycle. Patients who did not achieve a partial (PR) or complete (CR) remission at restaging after either 3 or 6 cycles were taken off study. Responders after 6 cycles had stem cell (SC) mobilization using filgrastim and plerixafor (if necessary) within 4 weeks of the end of induction. SC mobilization, harvesting, and reinfusion were performed per standard institutional protocol. A minimum collection of 2x106 CD34+ cells/kg was required to proceed to autologous stem cell transplant. Conditioning was comprised of gemcitabine 2700 mg/m2 on days -8 and -3, IV busulfan 105 mg/m2 days -8 to -5, and melphalan 60 mg/m2 given daily on days -3 and -2 (per MD Andersen protocol).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Benefit of Aortic Stent-graft in Patients With Distal Aortic Dissection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Uncomplicated distal aortic dissection~* Initial false lumen diameter \>= 22 mm~Exclusion Criteria:~* Old age (\> 75 years old)~* Other comorbidity or malignancy with life expectancy \< 5 years~* Complicated dissection requiring aortic surgery or intervention~* Sudden death in acute phase~* Marfan syndrome

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Early intervention (Type: ACTIVE_COMPARATOR): Early intervention: stent-graft just after acute phase
- Conservative (Type: NO_INTERVENTION): Conservative: medial follow-up without early intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PET / CT With 18F-FDG: Does it Optimize the I 123-MIBG Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with ischemic heart disease with heart failure~* Patients who received myocardial perfusion scintigraphy~* Indication for the implantation of an ICD installed according to current recommendations : LVEF \<30% and NYHA (New York Heart Association) stage II, III.~* The subject must have given his informed consent and signed consent~* The subject must be a member or beneficiary of a social security system~Exclusion Criteria:~* Pregnant or lactating women~* History of open heart cardiovascular surgery~* Inability to sign informed consent (patient under guardianship)~* Patients with diabetes mellitus~* Patient with proven dementia~* Person refusing to sign the consent~* Someone who already has an ICD at baseline~* Life expectancy less than one year (NYHA IV, other diseases such as neoplastic disease in an advanced stage)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- The study population (Type: None): See inclusion and exclusion criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Coaching and Education for Diabetes Distress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has had a diagnosis of type 2 diabetes for at least 6 months~* Aged 18 to 75 years~* Most recent HbA1c taken within 30 days was ≥ 8.0~* At least moderate diabetes distress (a mean score ≥ 2.0 on the 17-item Diabetes Distress Scale).~Exclusion Criteria:~* Moderately-severe to severe depression: Patient Health Questionnaire (PHQ9) score ≥15~* Other severe mental health disorder (e.g. Alzheimer's, schizophrenia)~* Current pregnancy~* Severe diabetes complications or functional deficits (e.g. kidney failure requiring dialysis, amputation, blindness).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Arm (Type: EXPERIMENTAL): Participants in the intervention arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education.~Months 1 to 3: Six 30 to 45-minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement.~Month 3: Follow up distress-specific education.~Months 4 and 5: Two 30 to 45 minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement.
- Control Arm (Type: ACTIVE_COMPARATOR): Participants in the control arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education (same as for the intervention arm).~Month 3: Follow up distress-specific education (same as for the intervention arm).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues